Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Stock Exchange 603718.SS

Shanghai Hile Bio-Technology Co., Ltd. Revenue for the year ending December 31, 2023: USD 33.91 M

Shanghai Hile Bio-Technology Co., Ltd. Revenue is USD 33.91 M for the year ending December 31, 2023, a -22.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Shanghai Hile Bio-Technology Co., Ltd. Revenue for the year ending December 31, 2022 was USD 43.47 M, a -20.46% change year over year.
  • Shanghai Hile Bio-Technology Co., Ltd. Revenue for the year ending December 31, 2021 was USD 54.66 M, a 37.68% change year over year.
  • Shanghai Hile Bio-Technology Co., Ltd. Revenue for the year ending December 31, 2020 was USD 39.70 M, a -0.55% change year over year.
  • Shanghai Hile Bio-Technology Co., Ltd. Revenue for the year ending December 31, 2019 was USD 39.92 M, a 7.85% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
Shanghai Stock Exchange: 603718.SS

Shanghai Hile Bio-Technology Co., Ltd.

CEO Ms. Qun Lin
IPO Date May 15, 2015
Location China
Headquarters Economic Development Zone
Employees 295
Sector Health Care
Industries
Description

Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; inactivated vaccine for streptococcus suis; pseudorabies live vaccines; inactivated oil emulsion vaccine of porcine parvovirus disease; pathogenic porcine reproductive and respiratory syndrome live vaccines; transmissible gastroenteritis, porcine epidemic diarrhea, and porcine rotavirus triple live vaccines; porcine reproductive and respiratory syndrome live vaccines; swine transmissible gastroenteritis and swine epidemic diarrhea combined inactivated vaccines; porcine circovirus type 2 inactivated vaccines; and swine Japanese encephalitis live vaccines. It also provides chicken infectious bursal disease live vaccines; inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease and avian infectious bronchitis combined live vaccines; newcastle disease low virulent live vaccines; Marek's disease turkey herpes virus live vaccines; and fowlpox live vaccines. The company was founded in 1981 and is based in Shanghai, China.

Similar companies

600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd

USD 2.64

3.93%

300497.SZ

Jiangxi Fushine Pharmaceutical Co., Ltd.

USD 1.09

2.71%

603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd.

USD 1.22

0.91%

603896.SS

Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

USD 2.74

2.83%

603566.SS

Pulike Biological Engineering, Inc.

USD 1.61

2.71%

StockViz Staff

January 16, 2025

Any question? Send us an email